Work

CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers

Year: 2020

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2019.7429

Authors: Lida Mina, Ruben G.W. Quek, Johannes Ettl, Ying Chen, Miguel Martin, Zev A. Wainberg, Johann S. de Bono, Sara A. Hurvitz, Hope S. Rugo

Institutions: Banner MD Anderson Cancer Center, TUM Klinikum, Technical University of Munich, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria Gregorio Marañón, University of California, Los Angeles, UCLA Medical Center, Los Angeles Medical Center, Royal Marsden NHS Foundation Trust, UCLA Jonsson Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3012534988

FWCI:

Cites:

Cited by:

Related to: 10